Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: Long-term follow-up of an Eastern Cooperative Oncology Group study (E5493)

Leukemia and Lymphoma

Volumn 53, Issue 6, 2012, Pages 1137-1142

  Wiernik, Peter H ^a   Li, Hailun ^b   Weller, Edie ^b   Hochster, Howard S ^c   Horning, Sandra J ^d   Nazeer, Tipu ^e   Gordon, Leo I ^f   Habermann, Thomas M ^g   Minniti, Carl J ^h   Shapiro, Gary R ⁱ   Cassileth, Peter A ^j  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d STANFORD UNIVERSITY   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

^f NORTHWESTERN UNIVERSITY   (United States)

^g MAYO CLINIC   (United States)

^h Minniti Center for Oncology/Hematology   (United States)

ⁱ AURORA SINAI MEDICAL CENTER   (United States)

^j UNIVERSITY OF MIAMI   (United States)

more..

Author keywords

Chemotherapeutic approaches; Lymphoma and Hodgkin disease; Topotecan

Indexed keywords

CHLORMETHINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; PROCARBAZINE; TOPOTECAN; VINCRISTINE;

ADULT; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BONE MARROW; CANCER FATIGUE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; FEMALE; FOLLOW UP; GRANULOCYTOPENIA; HISTOPATHOLOGY; HUMAN; ILEUS; IMMUNOBLASTIC LYMPHOMA; INFECTION; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER DISEASE; LIVER TOXICITY; LUNG DISEASE; MALE; METABOLIC DISORDER; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PHLEBITIS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 84861355956     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.643406     Document Type: Article

References (21)

1. Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induced protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-14878. (Pubitemid 16211028)
2. Hsiang YH, Liu LF. Identification of mammalian topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;49:5077-5082.
3. Wang JC. DNA topoisomerases. Ann Rev Biochem 1985;54:665-697. (Pubitemid 15073661)
4. Creemers GJ, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer; results of a large European phase II study. J Clin Oncol 1996;14:3056-3061. (Pubitemid 26408798)
5. ten Bokkel Huinik W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997;15:2183-2193. (Pubitemid 27251118)
6. Hochster H, Liebes L, Speyer J, et al. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen. J Clin Oncol 1994;12:533-559.
7. Hochster H, Liebes L, Speyer J, et al. Effect of prolonged topotecan infusion on topoisomerase I levels: a phase I and pharmacodynamic study. Clin Cancer Res 1997;3:1245-1252. (Pubitemid 27362384)
8. Hochster H, Wadler S, Runowicz C, et al. Activity and pharmacodyamics of 21-day topotecan infusion in ovarian cancer patients previously treated with platinum-based chemotherapy. J Clin Oncol 1999;17:2553-2561. (Pubitemid 29368258)
9. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the ECOG. Am J Clin Oncol 1982;5:649-655.
10. Kaplan EL, Meier P. Non-parametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457-481.
11. Wiernik PH, Lossos IS, Tuscano JM, et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin ' s lymphoma. J Clin Oncol 2008;26:4952-4957.
12. Witzig TE, Vose JM, Zinzani PL, et al. An international phase II study of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin ' s lymphoma. Ann Oncol 2011;22:1622-1627.
13. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932. (Pubitemid 28446681)
14. Rummel MJ, Gregory SA. Bendamustine' s emerging role in the management of lymphoid malignancies. Semin Hematol 2011;48 (Suppl. 1):S24-S36.
15. Goy A, Younes A, Mclaughlin P, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin ' s lymphoma. J Clin Oncol 2005;23:667-675. (Pubitemid 46224166)
16. Beran M, Kantarjian HM. Topotecan (hycamptin) and topotecancontaining regimens in the treatment of hematologic malignancies. Ann NY Acad Sci 2000;922:247-259. (Pubitemid 32050258)
17. Kraut EH, Balcerzak SP, Young D, et al. A phase II study of topotecan in non-Hodgkin ' s lymphoma: an Ohio State University phase II research consortium study. Cancer Invest 2002;20:174-179. (Pubitemid 34205483)
18. Younes A, Preti HA, Hagemeister FB, et al. Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin' s lymphoma. Ann Oncol 2001;12:923-927. (Pubitemid 32725763)
19. Kancherla RR, Nair JS, Ahmed T, et al. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response. Cancer 2001;91:463-471. (Pubitemid 32105690)
20. Beran M, Kantarjian H, O' B rien S, et al. Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996;88: 2473-2479. (Pubitemid 26327496)
21. Beran M, Estey E, O 'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 1999;17: 2819-2830. (Pubitemid 29415240)